More than just hype

[Louise Pilote](1) implies that physicians who prescribed ramipril to more of their diabetic patients after the results of the HOPE study were publicized did so primarily because of marketing hype rather than solid research evidence. As a clinical epidemiologist and diabetes specialist, I am baffled...

Full description

Saved in:
Bibliographic Details
Published inCanadian Medical Association journal (CMAJ) Vol. 168; no. 13; pp. 1646; author reply 1647 - 1646
Main Authors Yusuf, Salim, Dagenais, Gilles
Format Journal Article
LanguageEnglish
Published Canada CMA Impact, Inc 24.06.2003
Subjects
Angiotensin-Converting Enzyme Inhibitors - economics
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Canada
Cardiovascular disease
Cardiovascular Diseases - prevention & control
Clinical Trials as Topic
Cost-Benefit Analysis
Drugs
Humans
Letters
Physiological aspects
Ramipril - economics
Ramipril - therapeutic use
Treatment
Canada
Online AccessGet full text
ISSN0820-3946
1488-2329

Cover

More Information
Summary:[Louise Pilote](1) implies that physicians who prescribed ramipril to more of their diabetic patients after the results of the HOPE study were publicized did so primarily because of marketing hype rather than solid research evidence. As a clinical epidemiologist and diabetes specialist, I am baffled by this position. The HOPE study(2)(3) was by far the largest clinical trial evaluating an ACE inhibitor and enrolled a much broader clinical population than its predecessors. It included a prespecified subgroup of 3577 diabetic participants, possibly more than the total number of diabetic subjects enrolled in all previous ACE inhibitor trials. Diabetic (and nondiabetic) subjects assigned to receive ramipril had statistically and clinically significant risk reductions for major cardiovascular events.
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
content type line 14
ObjectType-Commentary-1
ObjectType-Correspondence-2
content type line 23
ISSN:0820-3946
1488-2329